Fig. 3.

ARADRP identified by spatial covariance analysis of [¹⁸F]-FDG-PET scans from Aβ+ NCs and Aβ- NCs in the SILCODE cohort. (A) Abnormal metabolic covariance topography of the ARADRP from the SILCODE cohort showing negative (cold color) and positive (warm color) regions coded by Z-scores. (B) Individual pattern expression score of the Aβ+ NCs and the Aβ- NCs using the ARADRP identified from the SILCODE cohort; the ADNI cohort was used for validation (right). (C) Correlation analysis of the pattern expression scores among individuals in the SILCODE cohort; the patterns were derived from the ADNI and the SILCODE cohorts. Abbreviations: ADNI, Alzheimer’s Disease Neuroimaging Initiative, SILCODE, Sino Longitudinal Study on Cognitive Decline Aβ, β-amyloid NCs, cognitively normal controls ARADRP, at-risk Alzheimer’s disease-related metabolic pattern [18F]-FDG-PET, [18F]fluoro-2-deoxyglucose positron emission tomography.